OP-1250

OP-1250 · Olema Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for OP-1250, covering 2025-08-24 to 2025-11-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients [Phase 1]